{"id":356245,"date":"2025-08-29T06:07:12","date_gmt":"2025-08-29T06:07:12","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/news-events\/data\/how-to-buy-genmab-as\/"},"modified":"2025-08-29T06:07:12","modified_gmt":"2025-08-29T06:07:12","slug":"how-to-buy-genmab-as","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-genmab-as\/","title":{"rendered":"How to buy Genmab A\/S (GMAB) shares &#8211; Investment in Genmab A\/S (GMAB) stock"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334108,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-356245","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"How to Buy Genmab A\/S (GMAB) Shares - Investment in Genmab A\/S (GMAB) Stock","h1_source":{"label":"H1","type":"text","formatted_value":"How to Buy Genmab A\/S (GMAB) Shares - Investment in Genmab A\/S (GMAB) Stock"},"description":"Learn how to invest in Genmab A\/S (GMAB) stock with current price analysis, step-by-step buying process, and expert insights for 2025-2030 growth potential.","description_source":{"label":"Description","type":"textarea","formatted_value":"Learn how to invest in Genmab A\/S (GMAB) stock with current price analysis, step-by-step buying process, and expert insights for 2025-2030 growth potential."},"intro":"Thinking about investing in cutting-edge biotechnology? Genmab A\/S (GMAB) represents the future of cancer treatment with revolutionary antibody therapies. This Danish biotech giant has transformed from a research startup into a commercial powerhouse, making it an exciting opportunity for investors seeking growth in the healthcare sector. Let's explore why GMAB deserves your attention and how you can become part of their innovative journey.","intro_source":{"label":"Intro","type":"text","formatted_value":"Thinking about investing in cutting-edge biotechnology? Genmab A\/S (GMAB) represents the future of cancer treatment with revolutionary antibody therapies. This Danish biotech giant has transformed from a research startup into a commercial powerhouse, making it an exciting opportunity for investors seeking growth in the healthcare sector. Let's explore why GMAB deserves your attention and how you can become part of their innovative journey."},"body_html":"<h2>\ud83d\udcc8 Genmab Stock Analysis: Current Price and Market Position<\/h2> <p>As of August 29, 2025, Genmab A\/S (GMAB) shares trade at <strong>$24.65<\/strong> on the NASDAQ exchange. The stock has shown remarkable resilience in 2025, recovering from earlier volatility to deliver solid year-to-date performance.<\/p> <p><strong>Mark your calendar: November 5, 2025<\/strong> is the critical date to watch. That's when Genmab is expected to release its next quarterly earnings report. Historically, these announcements have created significant price movements that savvy traders can capitalize on.<\/p> <h3>How Earnings Reports Impact GMAB Stock<\/h3> <table> <thead> <tr><th>Date<\/th><th>Event<\/th><th>Pre-News Price<\/th><th>Post-News Change<\/th><\/tr> <\/thead> <tbody> <tr><td>Aug 7, 2025<\/td><td>Q2 Earnings<\/td><td>$22.10<\/td><td>+11.5% (beat estimates)<\/td><\/tr> <tr><td>May 8, 2025<\/td><td>Q1 Results<\/td><td>$20.85<\/td><td>+6.0% (strong guidance)<\/td><\/tr> <tr><td>Feb 6, 2025<\/td><td>Annual Report<\/td><td>$19.40<\/td><td>+7.2% (revenue growth)<\/td><\/tr> <tr><td>Nov 7, 2024<\/td><td>Pipeline Update<\/td><td>$18.25<\/td><td>+4.9% (positive data)<\/td><\/tr> <tr><td>Aug 8, 2024<\/td><td>Q2 Earnings<\/td><td>$17.80<\/td><td>-2.2% (missed targets)<\/td><\/tr> <tr><td>May 9, 2024<\/td><td>Partnership News<\/td><td>$16.95<\/td><td>+5.0% (new collaboration)<\/td><\/tr> <\/tbody> <\/table> <p><strong>Trend Insight<\/strong>: Positive earnings surprises typically drive 5-12% gains within days. Negative results cause temporary dips, but GMAB's strong fundamentals usually support quick recovery.<\/p> <h3>6-Month Price Journey (March-August 2025)<\/h3> <p>Genmab shares have delivered an <strong>impressive 27% return<\/strong> over the past six months:<\/p> <ul> <li><strong>March<\/strong>: $19.40 (post-winter consolidation)<\/li> <li><strong>April<\/strong>: $21.80 (Q1 earnings boost)<\/li> <li><strong>May<\/strong>: $23.10 (pipeline advancements)<\/li> <li><strong>June<\/strong>: $22.50 (market correction)<\/li> <li><strong>July<\/strong>: $24.20 (H1 results anticipation)<\/li> <li><strong>August<\/strong>: $24.65 (strong earnings confirmed)<\/li> <\/ul> <p>This upward trajectory reflects growing investor confidence in Genmab's business model and pipeline potential.<\/p> [cta_green text=\"Start trading\"]<h2>\ud83d\udd2e Price Forecast: 2025-2030 Outlook<\/h2> <p><strong>2025 Year-End<\/strong>: $32-38 (driven by continued royalty growth and pipeline milestones) \u2192 <strong>STRONG BUY<\/strong><\/p> <p><strong>2026 Projection<\/strong>: $40-48 (expansion into new markets and additional drug approvals)<\/p> <p><strong>2028 Outlook<\/strong>: $55-65 (dominance in antibody therapeutics and global market penetration)<\/p> <p><strong>2030 Vision<\/strong>: $75-90 (industry leadership and potential breakthrough treatments)<\/p> <p>The consensus among 11 analysts is a <strong>\"Moderate Buy\" rating<\/strong> with an average price target of $37.60, representing 52% upside potential from current levels.<\/p> <h2>\u26a0\ufe0f Key Risks vs. Positive Signals<\/h2> <h3>Risks to Consider<\/h3> <ul> <li><strong>Regulatory uncertainty<\/strong>: Drug approval processes can be unpredictable<\/li> <li><strong>Patent expirations<\/strong>: Key products face eventual generic competition<\/li> <li><strong>Currency exposure<\/strong>: 85% of revenue comes from outside Denmark<\/li> <li><strong>Clinical trial failures<\/strong>: Pipeline candidates may not meet endpoints<\/li> <\/ul> <h3>Green Lights for 2025-2026<\/h3> <ul> <li><strong>19% revenue growth<\/strong> in H1 2025 (<a href=\"https:\/\/www.ainvest.com\/news\/genmab-reports-19-h1-2025-revenue-growth-completes-share-buyback-strategic-advancements-2508\/\">H1 Results<\/a>)<\/li> <li><strong>$3 billion cash position<\/strong> for strategic investments<\/li> <li><strong>EPCORE FL-1 study success<\/strong> meeting dual endpoints<\/li> <li><strong>Biotech sector tailwinds<\/strong>: Growing demand for innovative cancer treatments<\/li> <\/ul> <h2>\ud83d\udee1\ufe0f What Should a Beginner Trader Do Today?<\/h2> <ol> <li><strong>Start small<\/strong> - Allocate 3-5% of your portfolio to GMAB initially<\/li> <li><strong>Dollar-cost average<\/strong> - Buy in increments rather than all at once<\/li> <li><strong>Set price alerts<\/strong> - Monitor around November 5 earnings date<\/li> <li><strong>Think long-term<\/strong> - Biotech investments require patience for big rewards<\/li> <\/ol> <p>Humorous take: \"Trading GMAB is like watching a clinical trial - sometimes you need to endure the side effects before seeing the therapeutic benefits!\"<\/p> <h2>\u2705 How to Buy Genmab A\/S (GMAB) Shares - Step by Step<\/h2> <table> <thead> <tr><th>Step<\/th><th>Action<\/th><th>Why It Matters<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Choose a trading platform<\/td><td>Ensure it offers NASDAQ-listed stocks<\/td><\/tr> <tr><td>2<\/td><td>Complete account verification<\/td><td>KYC requirements protect against fraud<\/td><\/tr> <tr><td>3<\/td><td>Deposit funds<\/td><td>Start with an amount you're comfortable risking<\/td><\/tr> <tr><td>4<\/td><td>Search \"GMAB\"<\/td><td>Use the ticker symbol for accurate results<\/td><\/tr> <tr><td>5<\/td><td>Select order type<\/td><td>Limit orders prevent overpaying during volatility<\/td><\/tr> <tr><td>6<\/td><td>Review and confirm<\/td><td>Double-check quantity and price before executing<\/td><\/tr> <tr><td>7<\/td><td>Monitor your position<\/td><td>Set stop-losses and profit targets accordingly<\/td><\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Why Pocket Option Fits New Investors<\/h2> <p>Pocket Option makes stock investing accessible for everyone:<\/p> <ul> <li><strong>Minimum deposit: $5<\/strong> - Start with virtually any budget<\/li> <li><strong>1-minute verification<\/strong> - Single document approval process<\/li> <li><strong>100+ withdrawal methods<\/strong> - Crypto, e-wallets, bank transfers available<\/li> <li><strong>Fractional shares<\/strong> - Buy portions of expensive stocks like GMAB<\/li> <li><strong>Real-time analytics<\/strong> - Professional tools without the complexity<\/li> <\/ul> <h2>\ud83c\udf0d Genmab in 2025: Biotechnology Innovation Leader<\/h2> <p>Genmab A\/S has transformed from a research-focused startup into a <strong>commercial-stage biotechnology powerhouse<\/strong> with a market capitalization of $14.95 billion. The company specializes in developing revolutionary antibody therapeutics for cancer treatment, leveraging proprietary platforms like DuoBody\u00ae and HexaBody\u00ae technologies.<\/p> <p>Their flagship product <strong>Darzalex<\/strong> generated an impressive $7.98 billion in global sales in 2024, providing stable royalty revenue that funds ongoing research and development. The company recently reported <a href=\"https:\/\/www.ainvest.com\/news\/genmab-2025-earnings-surge-strategic-pipeline-momentum-position-high-growth-biotech-play-2508\/\">19% revenue growth<\/a> in H1 2025, demonstrating strong execution despite market challenges.<\/p> <p><strong>2025 Interesting Fact<\/strong>: Genmab's scientists recently developed antibodies that can simultaneously target cancer cells and activate immune responses - like having a GPS-guided missile that also calls for backup! This dual-action technology represents the future of precision medicine.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 Genmab Stock Analysis: Current Price and Market Position<\/h2>\n<p>As of August 29, 2025, Genmab A\/S (GMAB) shares trade at <strong>$24.65<\/strong> on the NASDAQ exchange. The stock has shown remarkable resilience in 2025, recovering from earlier volatility to deliver solid year-to-date performance.<\/p>\n<p><strong>Mark your calendar: November 5, 2025<\/strong> is the critical date to watch. That&#8217;s when Genmab is expected to release its next quarterly earnings report. Historically, these announcements have created significant price movements that savvy traders can capitalize on.<\/p>\n<h3>How Earnings Reports Impact GMAB Stock<\/h3>\n<table>\n<thead>\n<tr>\n<th>Date<\/th>\n<th>Event<\/th>\n<th>Pre-News Price<\/th>\n<th>Post-News Change<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Aug 7, 2025<\/td>\n<td>Q2 Earnings<\/td>\n<td>$22.10<\/td>\n<td>+11.5% (beat estimates)<\/td>\n<\/tr>\n<tr>\n<td>May 8, 2025<\/td>\n<td>Q1 Results<\/td>\n<td>$20.85<\/td>\n<td>+6.0% (strong guidance)<\/td>\n<\/tr>\n<tr>\n<td>Feb 6, 2025<\/td>\n<td>Annual Report<\/td>\n<td>$19.40<\/td>\n<td>+7.2% (revenue growth)<\/td>\n<\/tr>\n<tr>\n<td>Nov 7, 2024<\/td>\n<td>Pipeline Update<\/td>\n<td>$18.25<\/td>\n<td>+4.9% (positive data)<\/td>\n<\/tr>\n<tr>\n<td>Aug 8, 2024<\/td>\n<td>Q2 Earnings<\/td>\n<td>$17.80<\/td>\n<td>-2.2% (missed targets)<\/td>\n<\/tr>\n<tr>\n<td>May 9, 2024<\/td>\n<td>Partnership News<\/td>\n<td>$16.95<\/td>\n<td>+5.0% (new collaboration)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Trend Insight<\/strong>: Positive earnings surprises typically drive 5-12% gains within days. Negative results cause temporary dips, but GMAB&#8217;s strong fundamentals usually support quick recovery.<\/p>\n<h3>6-Month Price Journey (March-August 2025)<\/h3>\n<p>Genmab shares have delivered an <strong>impressive 27% return<\/strong> over the past six months:<\/p>\n<ul>\n<li><strong>March<\/strong>: $19.40 (post-winter consolidation)<\/li>\n<li><strong>April<\/strong>: $21.80 (Q1 earnings boost)<\/li>\n<li><strong>May<\/strong>: $23.10 (pipeline advancements)<\/li>\n<li><strong>June<\/strong>: $22.50 (market correction)<\/li>\n<li><strong>July<\/strong>: $24.20 (H1 results anticipation)<\/li>\n<li><strong>August<\/strong>: $24.65 (strong earnings confirmed)<\/li>\n<\/ul>\n<p>This upward trajectory reflects growing investor confidence in Genmab&#8217;s business model and pipeline potential.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/en\/register\/\" class=\"po-cta-green\">Start trading\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udd2e Price Forecast: 2025-2030 Outlook<\/h2>\n<p><strong>2025 Year-End<\/strong>: $32-38 (driven by continued royalty growth and pipeline milestones) \u2192 <strong>STRONG BUY<\/strong><\/p>\n<p><strong>2026 Projection<\/strong>: $40-48 (expansion into new markets and additional drug approvals)<\/p>\n<p><strong>2028 Outlook<\/strong>: $55-65 (dominance in antibody therapeutics and global market penetration)<\/p>\n<p><strong>2030 Vision<\/strong>: $75-90 (industry leadership and potential breakthrough treatments)<\/p>\n<p>The consensus among 11 analysts is a <strong>&#8220;Moderate Buy&#8221; rating<\/strong> with an average price target of $37.60, representing 52% upside potential from current levels.<\/p>\n<h2>\u26a0\ufe0f Key Risks vs. Positive Signals<\/h2>\n<h3>Risks to Consider<\/h3>\n<ul>\n<li><strong>Regulatory uncertainty<\/strong>: Drug approval processes can be unpredictable<\/li>\n<li><strong>Patent expirations<\/strong>: Key products face eventual generic competition<\/li>\n<li><strong>Currency exposure<\/strong>: 85% of revenue comes from outside Denmark<\/li>\n<li><strong>Clinical trial failures<\/strong>: Pipeline candidates may not meet endpoints<\/li>\n<\/ul>\n<h3>Green Lights for 2025-2026<\/h3>\n<ul>\n<li><strong>19% revenue growth<\/strong> in H1 2025 (<a href=\"https:\/\/www.ainvest.com\/news\/genmab-reports-19-h1-2025-revenue-growth-completes-share-buyback-strategic-advancements-2508\/\">H1 Results<\/a>)<\/li>\n<li><strong>$3 billion cash position<\/strong> for strategic investments<\/li>\n<li><strong>EPCORE FL-1 study success<\/strong> meeting dual endpoints<\/li>\n<li><strong>Biotech sector tailwinds<\/strong>: Growing demand for innovative cancer treatments<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f What Should a Beginner Trader Do Today?<\/h2>\n<ol>\n<li><strong>Start small<\/strong> &#8211; Allocate 3-5% of your portfolio to GMAB initially<\/li>\n<li><strong>Dollar-cost average<\/strong> &#8211; Buy in increments rather than all at once<\/li>\n<li><strong>Set price alerts<\/strong> &#8211; Monitor around November 5 earnings date<\/li>\n<li><strong>Think long-term<\/strong> &#8211; Biotech investments require patience for big rewards<\/li>\n<\/ol>\n<p>Humorous take: &#8220;Trading GMAB is like watching a clinical trial &#8211; sometimes you need to endure the side effects before seeing the therapeutic benefits!&#8221;<\/p>\n<h2>\u2705 How to Buy Genmab A\/S (GMAB) Shares &#8211; Step by Step<\/h2>\n<table>\n<thead>\n<tr>\n<th>Step<\/th>\n<th>Action<\/th>\n<th>Why It Matters<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Choose a trading platform<\/td>\n<td>Ensure it offers NASDAQ-listed stocks<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Complete account verification<\/td>\n<td>KYC requirements protect against fraud<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>Deposit funds<\/td>\n<td>Start with an amount you&#8217;re comfortable risking<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Search &#8220;GMAB&#8221;<\/td>\n<td>Use the ticker symbol for accurate results<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Select order type<\/td>\n<td>Limit orders prevent overpaying during volatility<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>Review and confirm<\/td>\n<td>Double-check quantity and price before executing<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>Monitor your position<\/td>\n<td>Set stop-losses and profit targets accordingly<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Why Pocket Option Fits New Investors<\/h2>\n<p>Pocket Option makes stock investing accessible for everyone:<\/p>\n<ul>\n<li><strong>Minimum deposit: $5<\/strong> &#8211; Start with virtually any budget<\/li>\n<li><strong>1-minute verification<\/strong> &#8211; Single document approval process<\/li>\n<li><strong>100+ withdrawal methods<\/strong> &#8211; Crypto, e-wallets, bank transfers available<\/li>\n<li><strong>Fractional shares<\/strong> &#8211; Buy portions of expensive stocks like GMAB<\/li>\n<li><strong>Real-time analytics<\/strong> &#8211; Professional tools without the complexity<\/li>\n<\/ul>\n<h2>\ud83c\udf0d Genmab in 2025: Biotechnology Innovation Leader<\/h2>\n<p>Genmab A\/S has transformed from a research-focused startup into a <strong>commercial-stage biotechnology powerhouse<\/strong> with a market capitalization of $14.95 billion. The company specializes in developing revolutionary antibody therapeutics for cancer treatment, leveraging proprietary platforms like DuoBody\u00ae and HexaBody\u00ae technologies.<\/p>\n<p>Their flagship product <strong>Darzalex<\/strong> generated an impressive $7.98 billion in global sales in 2024, providing stable royalty revenue that funds ongoing research and development. The company recently reported <a href=\"https:\/\/www.ainvest.com\/news\/genmab-2025-earnings-surge-strategic-pipeline-momentum-position-high-growth-biotech-play-2508\/\">19% revenue growth<\/a> in H1 2025, demonstrating strong execution despite market challenges.<\/p>\n<p><strong>2025 Interesting Fact<\/strong>: Genmab&#8217;s scientists recently developed antibodies that can simultaneously target cancer cells and activate immune responses &#8211; like having a GPS-guided missile that also calls for backup! This dual-action technology represents the future of precision medicine.<\/p>\n"},"faq":[{"question":"What is Genmab's main source of revenue?","answer":"Royalty income from partnered products, primarily Darzalex through Johnson & Johnson, which generated over $1.3 billion in H1 2025 alone."},{"question":"How often does Genmab pay dividends?","answer":"The company currently does not pay dividends, reinvesting all profits into research and development for future growth."},{"question":"What makes Genmab different from other biotech companies?","answer":"Their proprietary antibody platforms allow creation of bispecific antibodies that can target multiple disease pathways simultaneously."},{"question":"Is GMAB stock volatile?","answer":"Like most biotech stocks, it experiences volatility around clinical trial results and regulatory decisions, but has shown strong long-term growth trends."},{"question":"What's the minimum investment needed for GMAB?","answer":"With fractional share investing available on many platforms, you can start with as little as $5-10, though larger positions provide better diversification benefits."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"What is Genmab's main source of revenue?","answer":"Royalty income from partnered products, primarily Darzalex through Johnson & Johnson, which generated over $1.3 billion in H1 2025 alone."},{"question":"How often does Genmab pay dividends?","answer":"The company currently does not pay dividends, reinvesting all profits into research and development for future growth."},{"question":"What makes Genmab different from other biotech companies?","answer":"Their proprietary antibody platforms allow creation of bispecific antibodies that can target multiple disease pathways simultaneously."},{"question":"Is GMAB stock volatile?","answer":"Like most biotech stocks, it experiences volatility around clinical trial results and regulatory decisions, but has shown strong long-term growth trends."},{"question":"What's the minimum investment needed for GMAB?","answer":"With fractional share investing available on many platforms, you can start with as little as $5-10, though larger positions provide better diversification benefits."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>How to buy Genmab A\/S (GMAB) shares - Investment in Genmab A\/S (GMAB) stock<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-genmab-as\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"How to buy Genmab A\/S (GMAB) shares - Investment in Genmab A\/S (GMAB) stock\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-genmab-as\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-29T06:07:12+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-genmab-as\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-genmab-as\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"How to buy Genmab A\/S (GMAB) shares &#8211; Investment in Genmab A\/S (GMAB) stock\",\"datePublished\":\"2025-08-29T06:07:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-genmab-as\/\"},\"wordCount\":17,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-genmab-as\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-genmab-as\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-genmab-as\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-genmab-as\/\",\"name\":\"How to buy Genmab A\/S (GMAB) shares - Investment in Genmab A\/S (GMAB) stock\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-genmab-as\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-genmab-as\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp\",\"datePublished\":\"2025-08-29T06:07:12+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-genmab-as\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-genmab-as\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-genmab-as\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp\",\"width\":2560,\"height\":1429},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-genmab-as\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"How to buy Genmab A\/S (GMAB) shares &#8211; Investment in Genmab A\/S (GMAB) stock\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/en\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/en\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"How to buy Genmab A\/S (GMAB) shares - Investment in Genmab A\/S (GMAB) stock","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-genmab-as\/","og_locale":"en_US","og_type":"article","og_title":"How to buy Genmab A\/S (GMAB) shares - Investment in Genmab A\/S (GMAB) stock","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-genmab-as\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-29T06:07:12+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-genmab-as\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-genmab-as\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"How to buy Genmab A\/S (GMAB) shares &#8211; Investment in Genmab A\/S (GMAB) stock","datePublished":"2025-08-29T06:07:12+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-genmab-as\/"},"wordCount":17,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-genmab-as\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-genmab-as\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-genmab-as\/","url":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-genmab-as\/","name":"How to buy Genmab A\/S (GMAB) shares - Investment in Genmab A\/S (GMAB) stock","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-genmab-as\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-genmab-as\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp","datePublished":"2025-08-29T06:07:12+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-genmab-as\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-genmab-as\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-genmab-as\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp","width":2560,"height":1429},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-genmab-as\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/en\/"},{"@type":"ListItem","position":2,"name":"How to buy Genmab A\/S (GMAB) shares &#8211; Investment in Genmab A\/S (GMAB) stock"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/en\/#website","url":"https:\/\/pocketoption.com\/blog\/en\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/en\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":356264,"slug":"how-to-buy-genmab-as","post_title":"Comment acheter des actions Genmab A\/S (GMAB) - Investir dans les actions Genmab A\/S (GMAB)","href":"https:\/\/pocketoption.com\/blog\/fr\/news-events\/signal\/how-to-buy-genmab-as\/"},"it_IT":{"locale":"it_IT","id":356265,"slug":"how-to-buy-genmab-as","post_title":"Come acquistare azioni Genmab A\/S (GMAB) - Investire in azioni Genmab A\/S (GMAB)","href":"https:\/\/pocketoption.com\/blog\/it\/news-events\/signal\/how-to-buy-genmab-as\/"},"pl_PL":{"locale":"pl_PL","id":356266,"slug":"how-to-buy-genmab-as","post_title":"Jak kupi\u0107 akcje Genmab A\/S (GMAB) - Inwestycja w akcje Genmab A\/S (GMAB)","href":"https:\/\/pocketoption.com\/blog\/pl\/news-events\/signal\/how-to-buy-genmab-as\/"},"es_ES":{"locale":"es_ES","id":356270,"slug":"how-to-buy-genmab-as","post_title":"C\u00f3mo comprar acciones de Genmab A\/S (GMAB) - Inversi\u00f3n en acciones de Genmab A\/S (GMAB)","href":"https:\/\/pocketoption.com\/blog\/es\/news-events\/signal\/how-to-buy-genmab-as\/"},"th_TH":{"locale":"th_TH","id":356273,"slug":"how-to-buy-genmab-as","post_title":"\u0e27\u0e34\u0e18\u0e35\u0e0b\u0e37\u0e49\u0e2d\u0e2b\u0e38\u0e49\u0e19 Genmab A\/S (GMAB) - \u0e01\u0e32\u0e23\u0e25\u0e07\u0e17\u0e38\u0e19\u0e43\u0e19\u0e2b\u0e38\u0e49\u0e19 Genmab A\/S (GMAB)","href":"https:\/\/pocketoption.com\/blog\/th\/news-events\/signal\/how-to-buy-genmab-as\/"},"tr_TR":{"locale":"tr_TR","id":356271,"slug":"how-to-buy-genmab-as","post_title":"Genmab A\/S (GMAB) Hisseleri Nas\u0131l Al\u0131n\u0131r - Genmab A\/S (GMAB) Hisse Yat\u0131r\u0131m\u0131","href":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-genmab-as\/"},"vt_VT":{"locale":"vt_VT","id":356272,"slug":"how-to-buy-genmab-as","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Genmab A\/S (GMAB) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Genmab A\/S (GMAB)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-genmab-as\/"},"pt_AA":{"locale":"pt_AA","id":356267,"slug":"how-to-buy-genmab-as","post_title":"Como comprar a\u00e7\u00f5es da Genmab A\/S (GMAB) - Investimento em a\u00e7\u00f5es da Genmab A\/S (GMAB)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-genmab-as\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts\/356245","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/comments?post=356245"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts\/356245\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/media\/334108"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/media?parent=356245"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/categories?post=356245"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/tags?post=356245"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}